Adverum Biotechnologies, Inc. has announced progress with yet another therapy designed to extend the time between anti-VEGF injections for treatment of wet age-related macular degeneration (wAMD). The company’s Investigational New Drug (IND) application has been approved for a multi-center study of ADVM-022, a novel gene therapy candidate for the treatment of wAMD. “We are excited […]
Four eye health stakeholder groups have come together to help define the focus of research in age-related macular degeneration (AMD). Their purpose was to prioritize clinical questions important for researchers to answer when developing clinical practice guidelines and identifying treatment outcomes important to patients. Participants in the initiative were: American Academy of Ophthalmology (AAO) Retina/Vitreous […]
Regeneron Pharmaceuticals has announced that the FDA has approved extending the dosage regimen of EYLEA, its proprietary drug for treatment of wet macular degeneration (AMD).The decision was based on second-year data from the Phase 3 VIEW 1 and 2 trials in which patients were treated with doses given at least every 12 weeks plus additional […]
For the past 18 years, reports have been published here on the slow progress of research for treatment of central serous chorioretinopathy (CSC). Sometimes misdiagnosed as early-onset age-related macular degeneration, CSC is a disease of the central retina (the macula) affecting mostly middle-aged males, and it is thought to be caused by over-production of stress […]
by Dan Roberts In view of a recent surge in media reporting about blue light damage from digital devices, it is important to remember that there is no scientific evidence that blue light from such devices causes eye damage. The sun, and full spectrum lamps which imitate the sun, are the two strongest and most common […]
As of June 2, 2018, the law requires that audio description for the blind and visually impaired be made available by all digital first-run movie theaters. Almost all applicable theaters have complied, and others are in the process of converting to digital and upgrading to include description equipment. The Federal Government defines audio description as […]
Genentech has announced positive, top line results from a Phase 2 study of its Port Delivery System (PDS) with Lucentis in people with wet age-related macular degeneration (AMD). The small, refillable eye implant, which is slightly longer than a grain of rice, is designed to allow people with wet AMD to go several months without […]
Allergan and Molecular Partners have announced the release of two positive clinical trials of a new treatment for wet age-related macular degeneration (wAMD). The trials, named SEQUOIA and CEDAR, demonstrated that the biological drug Abicipar is equal to Genentech’s Lucentis (ranibizumab), with the added benefit that Abicipar treatments are effective at up to 12-week dosages. […]
The drug Emixustat has been in Phase 1/2 trials since 2008 for treatment of dry macular degeneration. Disappointingly, the drug has now been found to be ineffective at reducing the growth rates of geographic atrophy (GA) in patients with age-related macular degeneration (AMD). Preclinical analysis of Emixustat indicated that it inhibited the activity of the […]
Age-related macular degeneration (AMD) is the most common cause of visual impairment in people over age 60. Because it affects millions of senior adults, it deserves a great deal of attention. Another common condition also deserving of consideration is dry eye. Dry eye often accompanies AMD, but only because it most commonly affects the same […]